The impact of HER2-Low expression in salivary duct carcinoma : Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy

Kano, Satoshi; Kawakita, Daisuke; Honma, Yoshitaka; Takahashi, Hideaki; Nakaguro, Masato; Utsumi, Yoshitaka; Saigusa, Natsuki; Hanazawa, Toyoyuki; Tsukahara, Kiyoaki; Okada, Takuro; Okami, Kenji; Yamazaki, Keisuke; Ueki, Yushi; Saito, Yuki; Ozawa, Hiroyuki; Arai, Tomoyuki; Shimizu, Akira; Hanyu, Kenji; Iwaki, Sho; Imaizumi, Sae; Sakai, Akihiro; Yamauchi, Mayu; Tanaka, Ryoko; Sato, Yuichiro; Yamamura, Koji; Sekimizu, Mariko; Imanishi, Yorihisa; Hirai, Hideaki; Sato, Yukiko; Urano, Makoto; Yamamoto, Hidetaka; Fushimi, Chihiro; Matsuki, Takashi; Nagao, Toshitaka; Tada, Yuichiro

The impact of HER2-Low expression in salivary duct carcinoma : Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy

Kano, Satoshi; Kawakita, Daisuke; Honma, Yoshitaka et al.

Oral oncology, 2025, 165, 107280

Permalink : https://hdl.handle.net/2115/97759

このアイテムのアクセス数:13件（2026-05-02 10:29 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数
HUSCAP_Manuscript revision 20250315	pdf	778 KB	6
Supplemental Figure 0705	pdf	687 KB	3
Supplemental Tables revision 20250315	docx	40.4 KB	2

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/97759
タイトル	The impact of HER2-Low expression in salivary duct carcinoma : Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy
著者	Kano, Satoshi ; Kawakita, Daisuke ; Honma, Yoshitaka ; Takahashi, Hideaki ; Nakaguro, Masato ; Utsumi, Yoshitaka ; Saigusa, Natsuki ; Hanazawa, Toyoyuki ; Tsukahara, Kiyoaki ; Okada, Takuro ; Okami, Kenji ; Yamazaki, Keisuke ; Ueki, Yushi ; Saito, Yuki ; Ozawa, Hiroyuki ; Arai, Tomoyuki ; Shimizu, Akira ; Hanyu, Kenji ; Iwaki, Sho ; Imaizumi, Sae ; Sakai, Akihiro ; Yamauchi, Mayu ; Tanaka, Ryoko ; Sato, Yuichiro ; Yamamura, Koji ; Sekimizu, Mariko ; Imanishi, Yorihisa ; Hirai, Hideaki ; Sato, Yukiko ; Urano, Makoto ; Yamamoto, Hidetaka ; Fushimi, Chihiro ; Matsuki, Takashi ; Nagao, Toshitaka ; Tada, Yuichiro
e-Rad_Researcher 00374421 著者名 Kano, Satoshi
著者名 Kawakita, Daisuke
著者名 Honma, Yoshitaka
著者名 Takahashi, Hideaki
著者名 Nakaguro, Masato
著者名 Utsumi, Yoshitaka
著者名 Saigusa, Natsuki
著者名 Hanazawa, Toyoyuki
著者名 Tsukahara, Kiyoaki
著者名 Okada, Takuro
著者名 Okami, Kenji
著者名 Yamazaki, Keisuke
著者名 Ueki, Yushi
著者名 Saito, Yuki
著者名 Ozawa, Hiroyuki
著者名 Arai, Tomoyuki
著者名 Shimizu, Akira
著者名 Hanyu, Kenji
著者名 Iwaki, Sho
著者名 Imaizumi, Sae
著者名 Sakai, Akihiro
著者名 Yamauchi, Mayu
著者名 Tanaka, Ryoko
著者名 Sato, Yuichiro
著者名 Yamamura, Koji
著者名 Sekimizu, Mariko
著者名 Imanishi, Yorihisa
著者名 Hirai, Hideaki
著者名 Sato, Yukiko
著者名 Urano, Makoto
著者名 Yamamoto, Hidetaka
著者名 Fushimi, Chihiro
著者名 Matsuki, Takashi
著者名 Nagao, Toshitaka
著者名 Tada, Yuichiro
言語	英語
キーワード	Salivary duct carcinoma
	HER2
	HER2-low
	Androgen receptor
	Combined androgen blockade
	Salivary gland cancer
	Head and neck cancer
発行日	2025-04-18
出版者	Elsevier
収録物名	Oral oncology
巻(号)	165
ページ	107280
抄録	Objectives: Recent advances in systemic therapy for salivary duct carcinoma (SDC) have been driven by the development of HER2and androgen receptor (AR)-targeted therapies. Trastuzumab deruxtecan has proven effective not only in HER2-positive but also HER2-low breast and gastro-esophageal cancers. However, the significance of HER2-low expression in SDC remains unknown. This study aimed to investigate the clinicopathologic characteristics, prognostic implications, and impact on efficacy to AR-targeted therapy in HER2-low SDC. Materials and Methods: This was a multi-center, observational study. HER2 status was reclassified as follows: HER2-positive (IHC3+ or 2+/ISH+ ), HER2-low (IHC1+ or 2+/ISH-), and HER2-zero (IHC0). The subjects were compared in three groups: total population, curative treatment cohort, and AR-targeted therapy cohort. Results: The total population consisted of 526 patients, of whom, 271 (52 %), 184 (35 %), and 71 (13 %) had HER2-positive,-low, and-zero tumors, respectively. Sex, M category, histological origin, Ki67, and p53 expression differed significantly between the HER2-low and HER2-positive cases. No differences in relapse-free or overall survival were observed for HER2 status in the curative treatment cohort; however, in the AR-targeted therapy cohort, the HER2-low group had significantly better response rates (41.6 % vs. 18.9 %, Odds ratio = 0.30, P = 0.012) and longer median progression-free survival (6.9 vs. 4.2 months, Hazard ratio = 1.61, P = 0.029) than those of the HER2-positive group. Conclusion: HER2-low showed different clinicopathologic features from HER2-positive cases, with no prognostic differences observed in patients who underwent curative treatment. Still, HER2-low may be associated with the efficacy of AR-targeted therapy.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	© 2025. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
PISSN	1368-8375
EISSN	1879-0593
関連情報	PMID 40252453
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1016/j.oraloncology.2025.107280